Cargando…
Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old
CoronaVac is an inactivated SARS-CoV-2 vaccine that has been rolled out in several low and middle-income countries including Brazil, where it was the mainstay of the first wave of immunization of healthcare workers and the elderly population. We aimed to assess the T cell and antibody responses of v...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921991/ https://www.ncbi.nlm.nih.gov/pubmed/35300337 http://dx.doi.org/10.3389/fimmu.2022.812126 |
_version_ | 1784669433923371008 |
---|---|
author | Medeiros, Giuliana X. Sasahara, Greyce Luri Magawa, Jhosiene Y. Nunes, João Paulo S. Bruno, Fernanda R. Kuramoto, Andreia C. Almeida, Rafael R. Ferreira, Marcelo A. Scagion, Guilherme P. Candido, Érika D. Leal, Fabyano B. Oliveira, Danielle B. L. Durigon, Edison L. Silva, Roberto Carlos V. Rosa, Daniela S. Boscardin, Silvia B. Coelho, Verônica Kalil, Jorge Santos, Keity S. Cunha-Neto, Edecio |
author_facet | Medeiros, Giuliana X. Sasahara, Greyce Luri Magawa, Jhosiene Y. Nunes, João Paulo S. Bruno, Fernanda R. Kuramoto, Andreia C. Almeida, Rafael R. Ferreira, Marcelo A. Scagion, Guilherme P. Candido, Érika D. Leal, Fabyano B. Oliveira, Danielle B. L. Durigon, Edison L. Silva, Roberto Carlos V. Rosa, Daniela S. Boscardin, Silvia B. Coelho, Verônica Kalil, Jorge Santos, Keity S. Cunha-Neto, Edecio |
author_sort | Medeiros, Giuliana X. |
collection | PubMed |
description | CoronaVac is an inactivated SARS-CoV-2 vaccine that has been rolled out in several low and middle-income countries including Brazil, where it was the mainstay of the first wave of immunization of healthcare workers and the elderly population. We aimed to assess the T cell and antibody responses of vaccinated individuals as compared to convalescent patients. We detected IgG against SARS-CoV-2 antigens, neutralizing antibodies against the reference Wuhan SARS-CoV-2 strain and used SARS-CoV-2 peptides to detect IFN-g and IL-2 specific T cell responses in a group of CoronaVac vaccinated individuals (N = 101) and convalescent (N = 72) individuals. The frequency among vaccinated individuals, of whom 96% displayed T cell and/or antibody responses to SARS-CoV-2, is comparable to 98.5% responses of convalescent individuals. We observed that among vaccinated individuals, men and individuals 55 years or older developed significantly lower anti-RBD, anti-NP and neutralization titers against the Wuhan strain and antigen-induced IL-2 production by T cells. Neutralizing antibody responses for Gamma variant were even lower than for the Wuhan strain. Even though some studies indicated CoronaVac helped reduce mortality among elderly people, considering the appearance of novel variants of concern, CoronaVac vaccinated individuals above 55 years old are likely to benefit from a heterologous third dose/booster vaccine to increase immune response and likely protection. |
format | Online Article Text |
id | pubmed-8921991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89219912022-03-16 Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old Medeiros, Giuliana X. Sasahara, Greyce Luri Magawa, Jhosiene Y. Nunes, João Paulo S. Bruno, Fernanda R. Kuramoto, Andreia C. Almeida, Rafael R. Ferreira, Marcelo A. Scagion, Guilherme P. Candido, Érika D. Leal, Fabyano B. Oliveira, Danielle B. L. Durigon, Edison L. Silva, Roberto Carlos V. Rosa, Daniela S. Boscardin, Silvia B. Coelho, Verônica Kalil, Jorge Santos, Keity S. Cunha-Neto, Edecio Front Immunol Immunology CoronaVac is an inactivated SARS-CoV-2 vaccine that has been rolled out in several low and middle-income countries including Brazil, where it was the mainstay of the first wave of immunization of healthcare workers and the elderly population. We aimed to assess the T cell and antibody responses of vaccinated individuals as compared to convalescent patients. We detected IgG against SARS-CoV-2 antigens, neutralizing antibodies against the reference Wuhan SARS-CoV-2 strain and used SARS-CoV-2 peptides to detect IFN-g and IL-2 specific T cell responses in a group of CoronaVac vaccinated individuals (N = 101) and convalescent (N = 72) individuals. The frequency among vaccinated individuals, of whom 96% displayed T cell and/or antibody responses to SARS-CoV-2, is comparable to 98.5% responses of convalescent individuals. We observed that among vaccinated individuals, men and individuals 55 years or older developed significantly lower anti-RBD, anti-NP and neutralization titers against the Wuhan strain and antigen-induced IL-2 production by T cells. Neutralizing antibody responses for Gamma variant were even lower than for the Wuhan strain. Even though some studies indicated CoronaVac helped reduce mortality among elderly people, considering the appearance of novel variants of concern, CoronaVac vaccinated individuals above 55 years old are likely to benefit from a heterologous third dose/booster vaccine to increase immune response and likely protection. Frontiers Media S.A. 2022-03-01 /pmc/articles/PMC8921991/ /pubmed/35300337 http://dx.doi.org/10.3389/fimmu.2022.812126 Text en Copyright © 2022 Medeiros, Sasahara, Magawa, Nunes, Bruno, Kuramoto, Almeida, Ferreira, Scagion, Candido, Leal, Oliveira, Durigon, Silva, Rosa, Boscardin, Coelho, Kalil, Santos and Cunha-Neto https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Medeiros, Giuliana X. Sasahara, Greyce Luri Magawa, Jhosiene Y. Nunes, João Paulo S. Bruno, Fernanda R. Kuramoto, Andreia C. Almeida, Rafael R. Ferreira, Marcelo A. Scagion, Guilherme P. Candido, Érika D. Leal, Fabyano B. Oliveira, Danielle B. L. Durigon, Edison L. Silva, Roberto Carlos V. Rosa, Daniela S. Boscardin, Silvia B. Coelho, Verônica Kalil, Jorge Santos, Keity S. Cunha-Neto, Edecio Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old |
title | Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old |
title_full | Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old |
title_fullStr | Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old |
title_full_unstemmed | Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old |
title_short | Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old |
title_sort | reduced t cell and antibody responses to inactivated coronavirus vaccine among individuals above 55 years old |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921991/ https://www.ncbi.nlm.nih.gov/pubmed/35300337 http://dx.doi.org/10.3389/fimmu.2022.812126 |
work_keys_str_mv | AT medeirosgiulianax reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold AT sasaharagreyceluri reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold AT magawajhosieney reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold AT nunesjoaopaulos reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold AT brunofernandar reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold AT kuramotoandreiac reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold AT almeidarafaelr reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold AT ferreiramarceloa reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold AT scagionguilhermep reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold AT candidoerikad reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold AT lealfabyanob reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold AT oliveiradaniellebl reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold AT durigonedisonl reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold AT silvarobertocarlosv reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold AT rosadanielas reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold AT boscardinsilviab reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold AT coelhoveronica reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold AT kaliljorge reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold AT santoskeitys reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold AT cunhanetoedecio reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold |